EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$43.07
+2.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 590.0K | 2.3M | — | — | — |
| Gross Profit | (590.0K) | (2.3M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 171.3M | 151.4M | 127.0M | 90.9M | 54.0M |
| SG&A Expense | 47.6M | 40.0M | 31.9M | 23.5M | 17.6M |
| General & Admin Expense | 47.6M | 40.0M | 31.9M | 23.5M | 17.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (590.0K) | (2.3M) | — | — | — |
| Total Operating Expenses | 218.3M | 189.1M | 158.8M | 114.4M | 71.7M |
| Cost and Expenses | 218.9M | 191.4M | 158.8M | 114.4M | 71.7M |
| Operating Income (EBIT) | (218.9M) | (191.4M) | (158.8M) | (114.4M) | (71.7M) |
| Non-Operating | |||||
| Interest Income | 21.7M | 23.6M | 25.0M | 14.2M | 2.7M |
| Interest Expense | — | — | — | — | 4.0M |
| Net Interest Income | 21.7M | 23.6M | 25.0M | 14.2M | (1.4M) |
| Other Non-Op Income/Expense | 21.7M | 23.6M | 25.0M | 14.2M | 4.0M |
| Non-Operating Income (excl Interest) | (21.7M) | (23.6M) | (25.0M) | (14.2M) | (8.0M) |
| EBT (Pre-Tax Income) | (197.2M) | (167.8M) | (133.8M) | (100.2M) | (67.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (197.2M) | (167.8M) | (133.8M) | (100.2M) | (67.6M) |
| Earnings from Cont. Ops | (197.2M) | (167.8M) | (133.8M) | (100.2M) | (67.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (197.2M) | (167.8M) | (133.8M) | (100.2M) | (67.6M) |
| Per Share | |||||
| Basic EPS | ($1.85) | ($1.63) | ($1.45) | ($1.57) | ($1.26) |
| Diluted EPS | ($1.85) | ($1.63) | ($1.45) | ($1.57) | ($1.26) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 107.7M | 102.9M | 92.4M | 63.7M | 53.6M |
| Diluted Shares Outstanding | 107.7M | 102.9M | 92.4M | 63.7M | 53.6M |
| Profitability Metrics | |||||
| EBITDA | (197.2M) | (165.5M) | (131.5M) | (98.4M) | (63.1M) |
| D&A | 10.0K | 2.3M | 2.3M | 1.7M | 538.0K |
| EBIT | (197.2M) | (167.8M) | (133.8M) | (100.2M) | (63.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026